A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population

References

• SchwartzPJWoosleyRLPredicting the unpredictable: drug-induced QT prolongation and torsades de pointesJ Am Coll Cardiol201667131639165027150690
   PubMed Web of Science ®Google Scholar
• IfteniPCorrellCUBurteaVKaneJMManuPSudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatientsSchizophr Res20141551–3727624704220
   PubMed Web of Science ®Google Scholar
• RayWAChungCPMurrayKTHallKSteinCMAtypical antipsychotic drugs and the risk of sudden cardiac deathN Engl J Med2009360322523519144938
   PubMed Web of Science ®Google Scholar
• GirardinFSztajzelJCardiac adverse reactions associated with psychotropic drugsDialogues Clin Neurosci2007919295
   Google Scholar
• BuckleyNASandersPCardiovascular adverse effects of antipsychotic drugsDrug Saf200023321522811005704
   PubMed Web of Science ®Google Scholar
• BeachSRCelanoCMNoseworthyPAJanuzziJLHuffmanJCQTc prolongation, torsades de pointes, and psychotropic medicationsPsychosomatics201354111323295003
   PubMed Web of Science ®Google Scholar
• MalikMCammAJEvaluation of drug-induced QT interval prolongation: implications for drug approval and labellingDrug Saf200124532335111419561
   PubMed Web of Science ®Google Scholar
• DarpoBSpectrum of drugs prolonging QT interval and the incidence of torsades de pointesEur Heart J20013Suppl KK70K80
   Web of Science ®Google Scholar
• ChingCKTanECCongenital long QT syndromes: clinical features, molecular genetics and genetic testingExpert Rev Mol Diagn20066336537416706739
   PubMed Web of Science ®Google Scholar
• RodenDMViswanathanPCGenetics of acquired long QT syndromeJ Clin Invest200511582025203216075043
   PubMed Web of Science ®Google Scholar
• CubedduLXIatrogenic QT Abnormalities and fatal arrhythmias: mechanisms and clinical significanceCurr Cardiol Rev20095316617620676275
   PubMedGoogle Scholar
• ItohHCrottiLAibaTThe genetics underlying acquired long QT syndrome: impact for genetic screeningEur Heart J201637181456146426715165
   PubMed Web of Science ®Google Scholar
• TrinkleyKEPageRLLienHYamanouyeKTisdaleJEQT interval prolongation and the risk of torsades de pointes: essentials for cliniciansCurr Med Res Opin201329121719172624020938
   PubMed Web of Science ®Google Scholar
• WitchelHJHancoxJCNuttDJPsychotropic drugs, cardiac arrhythmia, and sudden deathJ Clin Psychopharmacol2003231587712544377
   PubMed Web of Science ®Google Scholar
• SilvestreJSO’NeillMFProusJREvidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychoticsJ Psychopharmacol201428432934024327451
   PubMed Web of Science ®Google Scholar
• Al-KhatibSMAllen LapointeNMKramerJMA survey of health care practitioners’ knowledge of the QT intervalJ Gen Intern Med200520539239615963159
   PubMed Web of Science ®Google Scholar
• FongemieJMAl-QadheebNSEstesNAAgreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluationPharmacotherapy201333658959723529904
   PubMed Web of Science ®Google Scholar
• Ojero-SenardABeneventJBondon-GuittonEA comparative study of QT prolongation with serotonin reuptake inhibitorsPsychopharmacology2017234203075308128770276
   PubMed Web of Science ®Google Scholar
• BarbuiCBighelliICarràGAntipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT IntervalPLoS One2016112e014821226840602
   PubMed Web of Science ®Google Scholar
• DanielssonBCollinJJonasdottir BergmanGBorgNSalmiPFastbomJAntidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults – a Swedish nationwide studyBr J Clin Pharmacol201681477378326574175
   PubMed Web of Science ®Google Scholar
• NosèMBighelliICastellazziMPrevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre studyEpidemiol Psychiatr Sci201625653254026467074
   PubMed Web of Science ®Google Scholar
• SchächteleSTümenaTGaßmannKGFrommMFMaasRCo-prescription of QT-interval prolonging drugs: an analysis in a large cohort of geriatric patientsPLoS One2016115e015564927192430
   PubMed Web of Science ®Google Scholar
• PoncetAGencerBBlondonMElectrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysisPLoS One2015106e012721326070071
   PubMed Web of Science ®Google Scholar
• RabkinSWImpact of age and sex on QT prolongation in patients receiving psychotropicsCan J Psychiatry201560520621426174524
   PubMed Web of Science ®Google Scholar
• TakeuchiHSuzukiTRemingtonGUchidaHAntipsychotic polypharmacy and corrected QT interval: a systematic reviewCan J Psychiatry201560521522226174525
   PubMed Web of Science ®Google Scholar
• ShahAAAftabACoverdaleJQTc prolongation with antipsychotics: is routine ECG monitoring recommended?J Psychiatr Pract201420319620624847993
   PubMed Web of Science ®Google Scholar
• GirardinFRGex-FabryMBerneyPShahDGaspozJMDayerPDrug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry studyAm J Psychiatry2013170121468147624306340
   PubMed Web of Science ®Google Scholar
• KatzDFSunJKhatriVQTc interval screening in an opioid treatment programAm J Cardiol201311271013101823820570
   PubMed Web of Science ®Google Scholar
• TranEDishmanBCitalopram-induced QTc prolongation: a brief review of the dataMent Health Clin201226139141
   Google Scholar
• Wenzel-SeifertKWittmannMHaenEQTc prolongation by psychotropic drugs and the risk of Torsade de PointesDtsch Arztebl Int20111084168769322114630
   PubMed Web of Science ®Google Scholar
• YangFDWangXQLiuXPSex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychoticsPsychopharmacology2011216191621301815
   PubMed Web of Science ®Google Scholar
• WahidiNJohnsonKMBrenzelAde LeonJTwo sudden and unexpected deaths of patients with schizophrenia associated with intramuscular injections of antipsychotics and practice guidelines to limit the use of high doses of intramuscular antipsychoticsCase Rep Psychiatry2016201694068131427597919
   PubMedGoogle Scholar
• ChouRCrucianiRAFiellinDAMethadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm SocietyJ Pain201415432133724685458
   PubMed Web of Science ®Google Scholar
• FanoeSKristensenDFink-JensenARisk of arrhythmia induced by psychotropic medications: a proposal for clinical managementEur Heart J201435201306131524644307
   PubMed Web of Science ®Google Scholar
• PacciardiBMauriMCargioliCIssues in the management of acute agitation: how much current guidelines consider safety?Front Psychiatry201342623675355
   PubMedGoogle Scholar
• de HertMVancampfortDCorrellCUGuidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluationBr J Psychiatry201119929910521804146
   PubMed Web of Science ®Google Scholar
• MartinJACampbellAKillipTQT interval screening in methadone maintenance treatment: report of a SAMHSA expert panelJ Addict Dis201130428330622026519
   PubMed Web of Science ®Google Scholar
• NielsenJGraffCKantersJKToftETaylorDMeyerJMAssessing QT interval prolongation and its associated risks with antipsychoticsCNS Drugs201125647349021649448
   PubMed Web of Science ®Google Scholar
• FishmanGIChughSSDimarcoJPSudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society WorkshopCirculation2010122222335234821147730
   PubMed Web of Science ®Google Scholar
• Modesto-LoweVBrooksDPetryNMethadone deaths: risk factors in pain and addicted populationsJ Gen Intern Med201025430530920087676
   PubMed Web of Science ®Google Scholar
• Institute for Safe Medication Practices Canada®Pharmacist Evaluation of QT Prolongation Risk and Recommendation. [Internet]2017 Available from: https://www.ismp-canada.org/ToolQit_QTprolongation/Accessed September 03, 2018
   Google Scholar
• TisdaleJEDrug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and managementCan Pharm J20161493139152
   Web of Science ®Google Scholar
• JardinCGPutneyDMichaudSAssessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agentsAnn Pharmacother201448219620224301687
   PubMed Web of Science ®Google Scholar
• TisdaleJEJaynesHAKingeryJREffectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes20147338139024803473
   PubMed Web of Science ®Google Scholar
• HaugaaKHBosJMTarrellRFMorlanBWCaraballoPJAckermanMJInstitution-wide QT alert system identifies patients with a high risk of mortalityMayo Clin Proc201388431532523541006
   PubMed Web of Science ®Google Scholar
• TisdaleJEJaynesHAKingeryJRDevelopment and validation of a risk score to predict QT interval prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes20136447948723716032
   PubMed Web of Science ®Google Scholar
• NachimuthuSAssarMDSchusslerJMDrug-induced QT interval prolongation: mechanisms and clinical managementTher Adv Drug Saf20123524125325083239
   PubMedGoogle Scholar
• DrewBJAckermanMJFunkMPrevention of Torsade de Pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation, endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized ElectrocardiologyCirculation201012181047106020142454
   PubMed Web of Science ®Google Scholar
• CredibleMeds® [homepage on the Internet]FAQs on QTdrugs lists, 2013 Available from: https://www.crediblemeds.org/everyone/articlesbrochures-library/consumerfaqAccessed September 3, 2018
   Google Scholar
• WoosleyRLBlackKHeiseCWRomeroKCredibleMeds.org: what does it offer?Trends Cardiovasc Med2018282949928801207
   PubMed Web of Science ®Google Scholar
• PanSDZhuLLChenMXiaPZhouQWeight-based dosing in medication use: what should we know?Patient Prefer Adherence20161054956027110105
   PubMed Web of Science ®Google Scholar
• LuscombeDKFactors influencing plasma drug concentrationsJ Int Med Res197751 Suppl8297863093
   PubMed Web of Science ®Google Scholar
• BoszkoMStanciuCNSurvey of EKG monitoring practices: a necessity or prolonged nuisance?Am J Psychiatry Residents’ Journal201711369
   Google Scholar
• CastellettiSDagradiFGouleneKA wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndromeInt J Cardiol2018266899429887480
   PubMed Web of Science ®Google Scholar
• AmesDCammJCookPMinimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia GroupEncephale2002286 Pt 1115124
   Web of Science ®Google Scholar
• GirgisSJMaroneyMELiuMTEvaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongationMent Health Clin20166417117729955466
   PubMedGoogle Scholar
• WarnierMJRuttenFHSouvereinPCde BoerAHoesAWde BruinMLAre ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidolPharmacoepidemiol Drug Saf201524770170826013175
   PubMed Web of Science ®Google Scholar
• VandaelEFoulonVDrug-induced QTc-prolongation: risk management in a community pharmacyJournal of the Malta College of Pharmacy Practice2017233712
   Google Scholar
• VicenteJZusterzeelRJohannesenLMechanistic model-informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation studyClin Pharmacol Ther20181031546628986934
   PubMed Web of Science ®Google Scholar
• ManuPKaneJMCorrellCUSudden deaths in psychiatric patientsJ Clin Psychiatry201172793694121672496
   PubMed Web of Science ®Google Scholar